Skip to main content
SpringerLink
Log in

Morbus Waldenström

Aktuelle Entwicklungen in Diagnostik und Therapie

Waldenström’s macroglobulinemia

Current developments in diagnostics and therapy

  • Schwerpunkt: Maligne Lymphome
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Der Morbus Waldenström (MW) ist eine seltene Subentität in der Gruppe der indolenten B‑Zell-Lymphome. Derzeit macht er lediglich 1–2 % aller hämatologischen Neoplasien aus. Die genetische Charakterisierung der Erkrankung erlaubt die Unterteilung des MW in Genotypen. Als therapeutischer Standard gilt bisher eine kombinierte Rituximab-/Chemotherapie. Eine weitere Therapieoption ist der Proteasominhibitor Bortezomib. Mit dem neu eingeführten oralen Bruton-Tyrosinkinase-Inhibitor Ibrutinib steht eine effektive chemotherapiefreie Behandlungsoption zur Verfügung.

Abstract

Waldenström’s macroglobulinemia (WM) is a rare subclass of the group of indolent B‑cell lymphomas representing only 1–2 % of all hematological neoplasms. Genetic characterization of the disease allows a subdivision of WM into genotypes. The combination of rituximab and chemotherapy is still the backbone of treatment. The proteasome inhibitor bortezomib is another effective treatment option. The newly introduced oral Bruton’s tyrosine kinase inhibitor ibrutinib provides an effective chemotherapy-free therapy for WM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Monge J, Braggio E, Ansell SM (2013) Genetic factors and pathogenesis of Waldenstrom’s macroglobulinemia. Curr Oncol Rep 15(5):450–456

    Article  CAS  PubMed  Google Scholar 

  2. Treon SP et al (2012) MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med 367(9):826–833

    Article  CAS  PubMed  Google Scholar 

  3. Yang G et al (2013) A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood 122(7):1222–1232

    Article  CAS  PubMed  Google Scholar 

  4. Treon SP et al (2014) Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood 123(18):2791–2796

    Article  CAS  PubMed  Google Scholar 

  5. Buske C, Leblond V (2013) How to manage Waldenstrom’s macroglobulinemia. Leukemia 27(4):762–772

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Buske C et al (2013) Waldenstrom’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 24(Suppl 6):vi155–vi159

    Google Scholar 

  7. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H,Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; Study group indolent Lymphomas (StiL) (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203–1210

    CAS  Google Scholar 

  8. Dimopoulos MA et al (2007) Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 25(22):3344–3349

    Article  CAS  PubMed  Google Scholar 

  9. Tedeschi A et al (2012) Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer 118(2):434–443

    Article  CAS  PubMed  Google Scholar 

  10. Morra E (2014) Carfilzomib: a new opportunity for WM patients. Blood 124(4):468–469

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Treon SP et al (2011) Maintenance Rituximab is associated with improved clinical outcome in rituximab naive patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol 154(3):357–362

    Article  CAS  PubMed  Google Scholar 

  12. Ghobrial IM et al (2010) Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 28(8):1422–1428

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Treon SP et al (2015) Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. N Engl J Med 372(15):1430–1440

    Article  CAS  PubMed  Google Scholar 

  14. Gertz MA et al (2012) Stem cell transplant for Waldenstrom macroglobulinemia: an underutilized technique. Bone Marrow Transplant 47(9):1147–1153

    Article  CAS  PubMed  Google Scholar 

  15. Treon SP (2015) How I treat Waldenstrom macroglobulinemia. Blood 126(6):721–732

    Article  CAS  PubMed  Google Scholar 

  16. Berentsen S (2011) How I manage cold agglutinin disease. Br J Haematol 153(3):309–317

    Article  PubMed  Google Scholar 

  17. Gopal AK et al (2014) PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370(11):1008–1018

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Goede V et al (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370(12):1101–1110

    Article  CAS  PubMed  Google Scholar 

  19. European Consortium for Waldenström’s Macroglobulinemia. http://www.ecwm.eu. Zugegriffen: 2015

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin III, Universitätsklinikum Ulm, Ulm, Deutschland

    A. Grunenberg &  C. Buske

  2. Comprehensive Cancer Center Ulm, Institut für experimentelle Tumorforschung, Universitätsklinikum Ulm, Ulm, Deutschland

    C. Buske

Authors
  1. A. Grunenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Buske
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Buske.

Ethics declarations

Interessenkonflikt

A. Grunenberg gibt an, dass kein Interessenkonflikt besteht. C. Buske gibt an, Beraterhonorare und Forschungsförderung von Janssen und Roche sowie Beraterhonorare von Janssen, Roche, Pfizer, Gilead und Celgene erhalten zu haben.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Additional information

Redaktion

W. Hiddemann, München

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grunenberg, A., Buske, C. Morbus Waldenström. Internist 57, 238–244 (2016). https://doi.org/10.1007/s00108-015-0005-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-015-0005-7

Schlüsselwörter

Keywords

Search

Navigation